G 蛋白偶联受体（GPCRs）是药物研发的重要靶点，但信号转导复杂阻碍了药物开发。研究人员探索了 GPCRs 的偏向性信号传导和细胞内调节剂，发现其在精准医学中具有潜在应用价值，有助于开发更安全有效的药物。 在生命科学和医学领域，药物研发一直是攻克 ...

GPCRs are the targets for around one third of ... “These receptors may not show any effects when knocked out in an animal model,” says Henderson, “but they must have some purpose or they ...

Nabla Bio's latest AI model update generates de novo antibodies for GPCRs with therapeutic-grade properties within a few ...

来自中国的研究人员通过激活小胶质细胞Gi-G蛋白偶联受体(Gi-GPCRs)，揭示了该信号通路如何抑制小胶质细胞突触动态、降低神经元活性并破坏神经网络同步化。这项研究为理解健康大脑中Gi-GPCR介导的神经调控机制提供了新见解，对神经科学领域具有重要意义。

“When Heptares formed, we chose to focus on GPCRs because we knew that targeting these receptors leads to drugs,” says Matt Barnes, president and head of R&D at Nxera Pharma. GPCRs are ...

As the largest family of cell surface receptors, GPCRs account for over one-third of drug screening efforts. Inositol-1-phosphate (IP1) is a metabolite of Gq signaling and has been shown to be very ...

Cisbio’s powerful HTRF technology allows for easy and thorough investigation into your GPCR targets of interest. Assays kits are available either ready to use, or you can easily have your own custom ...

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. A mere six months ago Verily ...

The latest price target for Structure Therapeutics (NASDAQ:GPCR) was reported by HC Wainwright & Co. on May 12, 2025. The analyst firm set a price target for $75.00 expecting GPCR to rise to ...